News

One study, presented at the Critical Care Congress, found that initiating remdesivir (Veklury) earlier did not significantly reduce the recovery time of hospitalized COVID-19 patients.

Masking requirements on public transportation was struck down by a federal judge late yesterday, which is leading to confusion for travelers today.

An analysis of readmissions after hospitalization with community-acquired pneumonia (CAP) in France found that few readmissions were avoidable, supporting criticism that the measure may lead to unfair penalties under pay-for-performance programs.

The greatest risk factors for recurrent Clostridioides difficile infection (CDI) were age of at least 65 years, severe primary CDI, and use of non-CDI antibiotics. Patients with these risk factors should be prioritized for bezlotoxumab therapy.

Advanced age and comorbidities were more accurate predictors of severe COVID-19 disease than innate immune response.

The meta-analysis included 6 studies, of which 5 were conducted in sub-Saharan Africa, showed that the diagnostic accuracy for Xpert testing was similar to the former symptom screening and rapid test format.

The technology platform could speed up the development of novel therapeutics to combat virulence.

The InspectIR COVID-19 Breathalyzer test detects chemical compounds in breath samples associated with a SARS-CoV-2 infection.

Antimicrobial stewardship efforts, such as education for healthcare providers, significantly decreased community-acquired pneumonia antibiotic prescriptions in COVID-19 patients.

The 36-fold increase in Omicron neutralizing titers in children between 5-11 years old is providing data for the companies to be able to file for an FDA EUA in this age group.

A study presented at the SHEA 2022 conference determined how common and severe breakthrough infections were for Pfizer-BioNTech, Moderna, and Janssen COVID-19 vaccine recipients.

The investigational shots utilizing their mRNA technology platform are being studied in adults in the US.

Merck announced today that their investigational 21-valent pneumococcal conjugate vaccine, V116, was granted Breakthrough Therapy Designation by the FDA.

Selecting initial antibiotic for ventilator-associated pneumonia from Gram staining and resistance records could reduce broad spectrum agents.

An examination of COVID-19 infections by occupation found that most cases occurred in people who worked in management and healthcare, and COVID-19 death rates were highest among building/grounds cleaning and maintenance employees.

A study found that hospital providers who prescribe unnecessarily high rates of antibiotics are likely to continue doing so over time.

In a small retrospective study, 7 of 11 patients experienced clinical improvement.

A large veterans health administration study estimated antibiotic use during the last 6 months of life for patients under hospice or palliative care.

The risk of a community-acquired C difficile infection was 7-fold higher for outpatients with antibiotic exposure.

During the COVID-19 pandemic, use of community-acquired pneumonia antibiotics increased significantly, while relative utilization of carbapenems decreased.

Patients scheduled for primary care appointments were more likely to get an influenza vaccine if they received a text message the night before indicating one was reserved for them, a new study shows.

Although the numbers overall remain relatively low, the city states the rising cases as the reason for its decision.

Humanigen’s monoclonal antibody lenzilumab shows promise for treating COVID-19 as new variants of the disease challenge the efficacy of other therapies.

Though many monoclonal antibodies were paused after demonstrated to be insufficient against the BA.1 Omicron subvariant, they may be more effective against BA.2.

Adding v-safe active monitoring to VAERS passive reporting produced "most comprehensive" program, and affirmed COVID-19 vaccine safety.

A systematic review of clinical trials found a high probability that fluvoxamine prevented COVID-19 hospitalizations in outpatient settings.

The risks of deep vein thrombosis, pulmonary embolism, and bleeding events were increased at 3 or more months after COVID-19 infection.

Company is working towards full Food and Drug Administration approval in the coming months.